原発性胆汁性胆管炎患者の掻痒に対するナルフラフィン塩酸塩

基本情報

NCT ID

NCT02659696

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

44

治験依頼者名

Teikyo University

概要

Nalfurafine hydrochloride is a selective kappa-opioid receptor agonist developed in Japan, and in May 2015 the use of nalfurafine hydrochloride was officially approved in Japan for pruritus in patients with chronic liver diseases including PBC. In the current study, the investigators aimed to assess pruritus and overall QOL before and after administration of nalfurafine hydrochloride in patients with PBC. Furthermore, the investigators took serum sample from the enrolled patients and examine the association of pruritus with possible biomarkers.

対象疾患

依頼者（Sponsor）

実施施設 (1)